4 results
The aim of this study is to evaluate the efficacy of three doses of S 066913 (5 mg, 25 mg and 100 mg o.d.) versus placebo administered for 4 weeks on atrial fibrillation and/or atrial tachycardia burden (AF/AT burden) in patients with paroxysmal…
The primary objective of this study is to characterize the real-world outcomes of high rate spinal cord stimulation (HR-SCS) therapy as an aid in the management of chronic intractable pain of the trunk, including unilateral or bilateral pain…
Primary:* To determine the effect of vedolizumab IV compared to adalimumab SC on clinical remission at Week 52.Secondary:* To evaluate the effect of vedolizumab IV compared to adalimumab SC on mucosal healing at Week 52.* To evaluate the effect of…
Primary:* To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in subjects with moderately to severely active UC who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0…